A phase 2, open-label, multicenter study of durvalumab (MEDI4736) ± tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS Meeting Abstract
| Authors: | O'Reilly, E. M.; Oh, D. Y.; Lee, M. A.; Dhani, N.; Armstrong, J.; Belli, R.; Ferro, S.; Ben, Y. |
| Abstract Title: | A phase 2, open-label, multicenter study of durvalumab (MEDI4736) ± tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 242s |
| Language: | English |
| ACCESSION: | WOS:000404665406114 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.TPS4150 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS4150 -- Source: Wos |
